HER2+ Early or Locally Advanced Breast Cancer
1 clinical trials · Condition
◉ Watch HER2+ Early or Locally Advanced Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer (NCT04900311) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-01 |
Track HER2+ Early or Locally Advanced Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.